Article

Conjunctiva, we hardly knew you

The author pokes fun at the obscurity of conjuctiva.

As a practical matter, I equate the term vestigial with something that serves no useful function or has no redeeming purpose. In other words, we'd be just as well off, if not better, without it. Good examples include the aforementioned appendix, the ear lobe, and the reality television show "Jersey Shore."

But what about the eye? Does this organ contain any vestigial structures? The question popped into my mind upon reading the abstracts for the second-largest ophthalmology meeting in the country (http://ascrsasoa2010.abstractcentral.com/planner/). Under the category of cosmetic procedures, I came across the interesting title, "Cosmetic conjunctival surgery to treat chronic hyperemic conjunctiva."

Over the past quarter century, as a resident, fellow, and corneal and external disease specialist, I have come to have a certain respect, if not affection, for the conjunctiva. Like other mucosal surfaces, it generates mucus, plays a role in immunity, and seems to play some sort of role in maintaining the health of the cornea and ocular surface.

On the other hand, it can become infected, swell, and become hyperemic; can become afflicted later in life with squamous cell neoplasia; and might play a negative role in certain autoimmune diseases, such as peripheral ulcerative keratitis.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.